Syngene International will hold its AGM on July 29, 2026, where it will declare a final dividend of ₹1.25 per share. The meeting also marks the appointment of Siddharth Mittal as the new MD & CEO.
Syngene International Announces AGM Date, Leadership Changes, and Dividend
Syngene International will hold its 33rd Annual General Meeting (AGM) on July 29, 2026, via Video Conferencing. The company announced a final dividend of ₹1.25 per equity share for the financial year ended March 31, 2026.
Reader Takeaway: Leadership transition and dividend payout; monitor industry headwinds.
What just happened
The company has scheduled its 33rd AGM for July 29, 2026. Key agenda items include the declaration of a final dividend of ₹1.25 per equity share and the appointment of Mr. Siddharth Mittal as the new Managing Director and Chief Executive Officer for a five-year term starting July 1, 2026. The record date for the dividend is June 26, 2026. M/s S. R. Batliboi & Associates LLP has been proposed as the statutory auditor for a five-year term.
Why this matters
This AGM signals a significant leadership transition at Syngene International with the onboarding of a new MD & CEO. The dividend payout offers a direct return to shareholders. Investors will be keen to understand the company's strategy under new leadership and its plans to address industry-specific challenges.
The backstory
For FY 2025-26, Syngene International reported standalone revenue of ₹3,490.7 crore and PAT of ₹304.9 crore. This marks a decrease in EBITDA and PAT compared to FY 2024-25 (EBITDA ₹988.1 crore, PAT ₹468.0 crore) and FY 2023-24 (EBITDA ₹966.8 crore, PAT ₹466.5 crore). Management attributes the profitability dip to the divestment of its Discovery business and external sector-wide risks like reduced biotech funding and the US Biosecure law's impact on the CDMO industry.
What changes now
With the appointment of Siddharth Mittal, the company anticipates a strategic direction under new leadership. The board level appointments aim to provide stability and expertise. The company is also making a strategic investment of USD 50 million in its US biologics facility (SUSA).
Risks to watch
Management has highlighted sector-wide risks including potential impacts from reduced biotech funding and the enforcement of the US Biosecure law. These could pose challenges to the CDMO industry and Syngene's growth prospects.
Peer comparison
Syngene operates in the Contract Development and Manufacturing Organization (CDMO) space. While specific peer financial data for FY 2025-26 is not detailed in this filing, the company's performance is viewed against the backdrop of broader industry trends affecting biotech funding and international regulations.
Context metrics (time-bound)
- FY 2025-26 Standalone Revenue: ₹3,490.7 crore
- FY 2025-26 Standalone EBITDA: ₹881.5 crore
- FY 2025-26 Standalone PAT: ₹304.9 crore
- Final Dividend: ₹1.25 per equity share
- Record Date for Dividend: June 26, 2026
- AGM Date: July 29, 2026
- New MD & CEO Term: 5 years, effective July 1, 2026
- MD & CEO Compensation: ₹25 crore annually
- Investment in SUSA: USD 50 million
What to track next
Investors should closely monitor the company's performance under new leadership, its strategic initiatives to mitigate industry risks, and its ability to drive sustained revenue growth and profitability. The effective management of the USD 50 million investment in the US facility will also be key.